Cited by 637Psychedelics and Drug StudiesParanormal Experiences and BeliefsReligion, Spirituality, and Psychology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Open access

Barrett, Frederick S, Johnson, Matthew W, Griffiths, Roland R·2015·Journal of Psychopharmacology

DOI 10.1177/0269881115609019PMC PMC5203697

Open this paper in CoChat — free account

Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants ( n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881115609019

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives
Hu, L., & Bentler, P. M. (1999) · Structural Equation Modeling A Multidisciplinary Journal · doi:10.1080/10705519909540118 · Cited by 108,788
lavaan : An R Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955
Alternative Ways of Assessing Model Fit
Browne, M. W., & Cudeck, R. (1992) · Sociological Methods & Research · doi:10.1177/0049124192021002005 · Cited by 27,200
Confirmatory factor analysis for applied research
Brown, T. A. (2007) · Choice Reviews Online · doi:10.5860/choice.44-2769 · Cited by 15,621
Testing Structural Equation Models.
Mueller, C. W., Bollen, K. A., & Long, J. S. (1994) · Contemporary Sociology A Journal of Reviews · doi:10.2307/2074955 · Cited by 14,211
EQS : structural equations program manual
Bentler, P. M. (1989) · Medical Entomology and Zoology · Cited by 9,669
Detection Theory: A User's Guide
Macmillan, N. A., & Creelman, C. D. (1991) · Cited by 5,415
A scaled difference chi-square test statistic for moment structure analysis
Satorra, A., & Bentler, P. M. (2001) · Psychometrika · doi:10.1007/bf02296192 · Cited by 5,282
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204

Show all 34 references

Research works printed but not linked: 3

Pahnke WN, 1963, Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness
Pahnke WN, 1967, LSD Man & Society, 60
Richards WA, 1975, Counseling, Peak Experiences and the Human Encounter with Death: An Empirical Study of the Efficacy of DPT-Assitance Counseling in Enhancing Quality of Life of Persons with Terminal Cancer and Their Closest Family Members

Sorted by citations

Items 101–200 of 635

“This Is Something That Changed My Life”: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
Mollaahmetoglu, O. M., Keeler, J., Ashbullby, K. J., Ketzitzidou-Argyri, E., Grabski, M., & Morgan, C. J. A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.695335 · Cited by 65
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 71
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 67
Self-citation
Broadening your mind to include others: the relationship between serotonergic psychedelic experiences and maladaptive narcissism.
van Mulukom, V., Patterson, R. E., & van Elk, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05568-y · Cited by 62
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.105 · Cited by 68
Examining changes in personality following shamanic ceremonial use of ayahuasca
Weiss, B., Miller, J. D., Carter, N. T., & Keith Campbell, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-84746-0 · Cited by 86
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01238 · Cited by 75
Self-citation
Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M. K., Garcia‐Romeu, A., Nayak, S. M., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab026 · Cited by 69
Self-citation
Sustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 67
A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
Reckweg, J., Mason, N. L., van Leeuwen, C., Toennes, S. W., Terwey, T. H., & Ramaekers, J. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760671 · Cited by 58
More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics
Aqil, M., & Roseman, L. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109300 · Cited by 63
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Mosurinjohn, S. C., Roseman, L., & Girn, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1077311 · Cited by 64
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 56
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 62
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
On the varieties of conscious experiences: Altered Beliefs Under Psychedelics (ALBUS)
Safron, A., Juliani, A., Reggente, N., Klimaj, V., & Johnson, M. W. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niae038 · Cited by 57
Self-citation
Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca
Agin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54
“, 2020, 2021; planned validation in a forthcoming article) as well as a well-established measure of mystical experience (MEQ-30; Barrett et al., 2015).”
BackgroundMethod
Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics
Glowacki, D. R., Wonnacott, M. D., Freire, R., Glowacki, B. R., Gale, E. M., Pike, J. E., de Haan, T., Chatziapostolou, M., & Metatla, O. (2020) · Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3313831.3376649 · Cited by 54
Rhythmic Chanting and Mystical States across Traditions
Perry, G., Polito, V., & Thompson, W. F. (2021) · Brain Sciences · doi:10.3390/brainsci11010101 · Cited by 63
Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
McAlpine, R. G., Blackburne, G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-53829-z · Cited by 55
Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs
Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 55
Self-citation
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Glowacki, D. R., Williams, R. R., Wonnacott, M., Maynard, O., Freire, R., Pike, J. E., & Chatziapostolou, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12637-z · Cited by 64
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan
Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05533-9 · Cited by 56
Self-citation
Psilocybin Therapeutic Research: The Present and Future Paradigm
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00048 · Cited by 49
Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality.
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 53
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02091-6 · Cited by 52
Psychological and physiological effects of extended DMT
Luan, L., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231196877 · Cited by 55
Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience
Kałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 53
Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants
Straumann, I., Ley, L., Holze, F., Becker, A., Klaiber, A., Wey, K., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01609-0 · Cited by 44
Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens: Psychometrics of Three Psychedelic Rating Scales
Bouso, J. C., Pedrero-Pérez, E. J., Gandy, S., & Alcázar-Córcoles, M. Á. (2016) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2545 · Cited by 48
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 48
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants
Rucker, J., Roberts, C., Seynaeve, M., Young, A. H., Suttle, B., Yamamoto, T., Ermakova, A. O., Dunbar, F., & Wiegand, F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241246857 · Cited by 47
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)
Wolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 40
Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey
Kuc, J., Kettner, H., Rosas, F. E., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., Nutt, D., & Carhart-Harris, R. L. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05999-1 · Cited by 41
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Exploring Emptiness and its Effects on Non-attachment, Mystical Experiences, and Psycho-spiritual Wellbeing: A Quantitative and Qualitative Study of Advanced Meditators
Gordon, W. V., Shonin, E., Dunn, T. J., Sapthiang, S., Kotera, Y., García‐Campayo, J., & Sheffield, D. (2018) · EXPLORE · doi:10.1016/j.explore.2018.12.003 · Cited by 39
What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review
Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 44
Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity
Gaddis, A., Lidstone, D. E., Nebel, M. B., Griffiths, R. R., Mostofsky, S. H., Mejia, A. F., & Barrett, F. S. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119434 · Cited by 46
Self-citation
A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond
Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 39
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Richardson, E., Patterson, R., Meltzer-Brody, S. E., McClure, R. W., & Tow, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050423-095712 · Cited by 39
Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans
Jylkkä, J. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00137 · Cited by 36
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“One such is the Revised MEQ30, developed by MacLean et al. (2012) (MacLean et al., 2012) from analyses of retrospective online surveys of mystical experiences occasioned by recreative use of psychedel-ics, assessed with the original MEQ-43 (Barrett et al., 2015; MacLean et al., 2012).”
Method
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
Søndergaard, A., Madsen, M. K., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.948729 · Cited by 37
Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America
Ching, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2025960 · Cited by 38
The Potential of Psychedelics for End of Life and Palliative Care
Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_278 · Cited by 37
Self-citation
Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s096318012200007x · Cited by 36
Self-citation
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-36184-3 · Cited by 33
Understanding subjective experience in psychedelic-assisted psychotherapy: The need for phenomenology
McMillan, R. M., & Fernandez, A. (2022) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/00048674221139962 · Cited by 34
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 41
Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings
Garel, N., Lévesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., Richard‐Devantoy, S., & Greenway, K. T. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1200393 · Cited by 33
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study
Siva, J. B., Barba, T., Kettner, H., Kuc, J., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231224217 · Cited by 34
Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression
Erritzøe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241237870 · Cited by 36
Dispositional Mindfulness May Be Associated with Deeper Connections with Nature
Hanley, A. W., Deringer, S. A., & Hanley, R. T. (2017) · Ecopsychology · doi:10.1089/eco.2017.0018 · Cited by 31
Meditation, well-being and cognition in heartfulness meditators – A pilot study
Sylapan, B. S., Nair, A. K., Jayanna, K., Malipeddi, S., Sathyanarayana, S., & Kutty, B. M. (2020) · Consciousness and Cognition · doi:10.1016/j.concog.2020.103032 · Cited by 32
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil
Daldegan‐Bueno, D., Maia, L. O., Massarentti, C. M., & Tófoli, L. F. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06063-2 · Cited by 34
Psychedelics alter metaphysical beliefsPreprint
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f6sjk · Cited by 34
How Chanting Relates to Cognitive Function, Altered States and Quality of Life
Perry, G., Polito, V., Sankaran, N., & Thompson, W. F. (2022) · Brain Sciences · doi:10.3390/brainsci12111456 · Cited by 38
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Breeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Vermetten, E. H. G. J. M., Kamphuis, J., van den Brink, W., & Schoevers, R. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06388-6 · Cited by 32
A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development
Whitfield, H. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727572 · Cited by 32
Psychedelics and hypnosis: Commonalities and therapeutic implications
Lemercier, C. E., & Terhune, D. B. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780714 · Cited by 32
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T. L., Hoskins, M. D., & Sessa, B. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2742 · Cited by 36
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 31
The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects
Bhatt, K. V., & Weissman, C. R. (2024) · npj Mental Health Research · doi:10.1038/s44184-023-00053-8 · Cited by 30
The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item
Strickland, J. C., Garcia‐Romeu, A., & Johnson, M. W. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0046 · Cited by 28
Self-citation
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 30
Translation and cultural adaptation of the States of Consciousness Questionnaire (SOCQ) and statistical validation of the Mystical Experience Questionnaire (MEQ30) in Brazilian Portuguese
Schenberg, E. E., Tófoli, L. F., REZINOVSKY, D., & da Silveira, D. X. (2017) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000105 · Cited by 31
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
Rush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 32
The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M., van Oorsouw, K. I. M., Delgado, A. R. O., & Ramaekers, J. G. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.857372 · Cited by 35
Dose-response relationships of LSD-induced subjective experiences in humans
Hirschfeld, T., Prugger, J., Majić, T., & Schmidt, T. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01588-2 · Cited by 29
Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects
Klaiber, A., Schmid, Y., Becker, A., Straumann, I., Erne, L., Jelušić, A., Thomann, J., Luethi, D., & Liechti, M. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03116-2 · Cited by 29
Hypnotic suggestion produces mystical-type experiences in the laboratory: A demonstration proof.
Lynn, S. J., & Evans, J. V. (2017) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000105 · Cited by 28
Classic psychedelics, health behavior, and physical health
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221135363 · Cited by 30
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Dourron, H. M., Nichols, C. D., Simonsson, O., Bradley, M. K., Carhart-Harris, R. L., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06517-1 · Cited by 36
Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia‐Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109127 · Cited by 28
Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 26
Self-citation
Treating Addiction
Tófoli, L. F., & de Araújo, D. B. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.005 · Cited by 35
A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting
Uthaug, M. V., Lancelotta, R., Bernal, A. M. O., Davis, A. K., & Ramaekers, J. G. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00123 · Cited by 25
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies
Stocker, K., Hartmann, M., Ley, L., Becker, A., Holze, F., & Liechti, M. E. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231199112 · Cited by 29
Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs
Tagliazucchi, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.812227 · Cited by 25
The Inventory of Nonordinary Experiences (INOE): Evidence of validity in the United States and India
Taves, A., Ihm, E. D., Wolf, M., Barlev, M., Kinsella, M., & Vyas, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287780 · Cited by 48
Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness
Havenith, M. N., Leidenberger, M., Brasanac, J., Corvacho, M., Figueiredo, I., Schwarz, L., Uthaug, M. V., Rakusa, S., Bernardic, M., Vasquez-Mock, L., et al. (2025) · Communications Psychology · doi:10.1038/s44271-025-00247-0 · Cited by 30
Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
Burmester, D., Madsen, M. K., Szabó, A., Aripaka, S. S., Stenbæk, D. S., Frøkjær, V. G., Elfving, B., Mikkelsen, J. D., Knudsen, G. M., & Fisher, P. M. (2022) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2022.100163 · Cited by 27
Psychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 26
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Antecedents of mystical experience and dread in intensive meditation.
Russ, S. L., & Elliott, M. S. (2017) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000119 · Cited by 23
Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects
Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.033 · Cited by 26
Self-citation
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21
Changes in high-order interaction measures of synergy and redundancy during non-ordinary states of consciousness induced by meditation, hypnosis, and auto-induced cognitive trance
Pradeep Kumar, G., Panda, R., Sharma, K., Adarsh, A., Annen, J., Martial, C., Faymonville, M.-É., Laureys, S., Sombrun, C., Ganesan, R. A., et al. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120623 · Cited by 22
Self-transcendence Predicts Better Pre- and Postoperative Outcomes in Two Randomized Clinical Trials of Brief Mindfulness-Based Interventions
Hanley, A. W., & Garland, E. L. (2022) · Mindfulness · doi:10.1007/s12671-022-01896-6 · Cited by 22
The use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 25

Authors: Barrett, F. S., Johnson, M. W., & Griffiths, R. R.
Affiliations: Johns Hopkins University (US)
Corresponding author: Barrett, Frederick S
ORCID: Barrett, Frederick S
Johnson, Matthew W
Griffiths, Roland R
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2015-10-06
Volume: 29
Issue: 11
Pages: 1182-1190
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881115609019
PMC: PMC5203697
OpenAlex: W2340085151
Cited by: 637
References: 34
Citations by year: 2026: 91 · 2025: 110 · 2024: 123 · 2023: 78 · 2022: 78 · 2021: 53 · 2020: 38 · 2019: 12 · 2018: 20 · 2017: 21 · 2016: 12
FWCI: 21.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Drug Abuse (R01DA003889, T32DA007209, R01DA03889)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords: psilocybin, mystical experience, psychedelic drug effects, questionnaire validation, factor structure, convergent validity, attitude change, well-being
MeSH terms: Administration, Oral, Hallucinogens, Humans, Mysticism, Psilocybin, Surveys and Questionnaires

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks